Table 3. Types of outcome measures used by 21 studies to quantify CD4 count response to cART.
| Measure of CD4 count response | Number of studies reporting this measure | Length of follow-up used in reporting this measure (months) |
|---|---|---|
| Immunologic success | ||
| Change in CD4 count from baselinea | 8 | 1; 3; 6; 9; 11; 12 |
| Absolute CD4 count at a specific follow-up timeb | 5 | 3; 6; 9; 11; 48 |
| Difference in the increase in CD4 count from baselinec | 3 | 6; 18; 22 |
| Increase of ≥50 cells/μL from baseline | 1 | 6 |
| Increase of ≥100 cells/μL from baseline | 1 | 12 |
| Absolute CD4 count >200 cells/μL | 1 | 12 |
| Absolute CD4 count >500 cells/μL | 1 | 30 |
| Rate of CD4 count increase from baseline (cells/month) | 1 | 30 |
| Difference in CD4 count recovery slope (cells/6 months) | 1 | 6; 48 |
| Median on treatment peak CD4 count | 1 | 53 |
| Median change between baseline and on treatment peak CD4 count | 1 | 53 |
| Immunologic failure | ||
| CD4 count decline from baseline, CD4 count <100 cells/μL, or 50% decline from peak CD4 count after ≥6 months of cART | 1 | 36 |
| Rate of immunologic failure | 1 | 36 |
| Absolute CD4 count <500 cells/μL | 1 | 30 |
Abbreviations: cART, combination antiretroviral therapy
a
An additional 2 studies provided data that enabled the calculation of this measure.
b
An additional 3 studies provided data that enabled the calculation of this measure.
c
An additional 10 studies provided data that enabled the calculation of this measure.